OTC · PJET
Priority Aviation, Inc.
$0.00$0.00 (0.0%)
Priority Aviation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
Loading market information…
OTC · ROSGQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Rosetta Genomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Rosetta Genomics Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics. The company leverages its proprietary microRNA technologies to offer a range of diagnostic assays, including RosettaGX Cancer Origin, which helps pinpoint the primary source of metastatic cancer; mi-KIDNEY, designed for classifying kidney tumors from pathological specimens; RosettaGX Reveal, used to interpret indeterminate thyroid fine-needle aspirate results; and various mi-LUNG diagnostic tests. In addition to its microRNA-based portfolio, Rosetta Genomics provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay. This assay serves as an adjunct to, rather than a substitute for, conventional diagnostic methods, aiding in the initial detection of bladder carcinoma in patients with hematuria and in the ongoing surveillance for tumor recurrence in those previously diagnosed with bladder cancer. The company also offers ERG/PTEN, which are FISH-based tests providing prognostic information for prostate cancer. Furthermore, Rosetta Genomics supplies ALK/ROS1, a set of FISH-based predictive tests specifically intended for individuals with late-stage lung cancer, along with PCR gene mutation analysis for patients with bladder, lung, colon, and melanoma cancers. Its diagnostic solutions are utilized by a diverse group of medical professionals, including oncologists, urologists, endocrinologists, and cytopathologists, empowering them to deliver improved patient care. The company holds a licensing agreement with Max Planck Innovation GmbH, securing rights to its patented microRNA technologies for both diagnostic applications and research initiatives. Moreover, Rosetta Genomics has entered into a collaborative partnership with Meir Medical Center to develop a microRNA classifier, focusing on non-small cell lung cancer patients being considered for immuno-oncology therapies. Established in 2000, Rosetta Genomics Ltd. maintains its headquarters in Rehovot, Israel.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:24 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Jun 1, 2011 |
| -$57.60-33.33% vs estimate |
| $0.00 |
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Priority Aviation, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$0.00$0.00 (0.0%)
MetaStat Inc’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
$0.00$0.00 (0.0%)
Motus GI Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.8% below the high.
$0.00$0.00 (0.0%)
Biocept, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
$0.00$0.00 (0.0%)
Adhera Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00$0.00 (0.0%)
Ontrak, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.88% below the high.
$0.00$0.00 (0.0%)
Sunset Island Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Cannabiz Mobile, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.02% below the high.
